CTNM · Contineum Therapeutics, Inc.
$17.19
+1.17 (+7.30%)
At close · Aug 21
Market Cap
$602.69M
Shares
37.62M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Carmine N. Stengone | President and Chief Executive Officer | $3,409,448 |
| Timothy R. Watkins | M.D., MSc. Chief Medical Officer and Head of Development | $1,763,323 |
| Peter T. Slover | Chief Financial Officer | $1,577,903 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Carmine N. Stengone | President and Chief Executive Officer | $4,900,039 |
| John S. Healy | General Counsel and Corporate Secretary | $2,562,489 |
| Stephen L. Huhn | Former Chief Medical Officer and Senior Vice President of Clinical Development | $2,121,674 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Carmine N. Stengone | President and Chief Executive Officer | $2,315,299 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Diego Miralles, M.D. | Class II director | Appointed | 2025-03-17 |
| Sarah Boyce | Chair of the Board’s Nominating and Corporate Governance Committee | Appointed | 2024-06-24 |
| Sarah Boyce | member of its Board | Appointed | 2024-06-24 |
| Troy Ignelzi | Class I director | Appointed | 2024-05-20 |
Key facts
CIK
1855175
CUSIP
21217B100
13F (30d)
99 filings
97 filers
Visit website
Investor relations